TITLE

UCB INITIATES PHASE III RIKRLTS TRIAL FOR EPILEPSY

PUB. DATE
December 2007
SOURCE
Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Phase III clinical trials of the antiepileptic drug (AED) in development of UCB, brivaracetam, are underway. It is an adjunctive therapy in patients with refractory partial-onset epilepsy. The proposed tradename for it is Rikelta&trade. Iris Loew-Friedrich, Global Head of Development of UCB, said that the start of the Phase III program for brivaracetam is a key milestone in the advancement of the epilepsy franchise of UCB and re-enforces their commitment to the development of new treatment options for people with epilepsy.
ACCESSION #
27616305

 

Related Articles

  • Designing Clinical Trials to Assess Antiepileptic Drugs as Monotherapy: Difficulties and Solutions. Perucca, Emilio // CNS Drugs;2008, Vol. 22 Issue 11, p917 

    Designing monotherapy trials in epilepsy is fraught with many hurdles, including diagnostic and classification difficulties, sparse information regarding the natural history of the disorder, and ethical objections to the use of placebo or a suboptimal comparator in a condition where the...

  • Eslicarbazepine Acetate: A Review of Its Use as Adjunctive Therapy in Refractory Partial-Onset Seizures. Keating, Gillian // CNS Drugs;Jul2014, Vol. 28 Issue 7, p583 

    Eslicarbazepine acetate (Aptiom, Zebinix) is approved for the adjunctive treatment of partial-onset seizures in adults aged ≥18 years. Adjunctive therapy with oral eslicarbazepine acetate 800 or 1,200 mg once daily was associated with a significantly lower standardized seizure frequency...

  • Public funding of AEDs cost effective in India.  // PharmacoEconomics & Outcomes News;Feb2016, Vol. 745 Issue 1, p29 

    The article discusses a study published in the journal "Epilepsia" by I. Megiddo and colleagues, in the January 14, 2016 issue, which shows that public funding of antiepileptic drugs (AEDs) for epilepsy patients in India appears to be cost effective.

  • Selection criteria for the clinical use of the newer antiepileptic drugs. Deckers, Charles L.P.; Knoester, P.D.; de Haan, G.J.; Keyser, A.; Renier, W.O.; Hekster, Y.A. // CNS Drugs;2003, Vol. 17 Issue 6, p405 

    In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy,...

  • Ethical issues of using placebo in antiepileptic drugs trials in Asia. Byung In Lee // Neurology Asia;2010 Supplement 1, Vol. 15 Issue S1, p29 

    Any human trials should be designed and conducted within the ethical framework of the "Declaration of Helsinki" stating that any new agent must be tested against standard, proven therapies when available. In the clinical development of antiepileptic drugs, a double-blinded, placebo-controlled...

  • Carbamazepine and Lamotrigine Plasma Concentrations in Epileptic Patients during Optimising Therapy. Krasniqi, Shaip; Neziri, Burim; Islami, Hilmi; Bauer, Steffen // Medicinski Arhiv;2010, Vol. 64 Issue 2, p80 

    Therapeutic monitoring of antiepileptic drugs is important in process of optimisation of therapy of epileptic patients. Carbamazepine (CBZ) and Lamotrigine [LMT) are important drugs in therapy of epileptic patients which requires the monitoring of concentration of these drugs in serum. Our study...

  • Clinical and Paraclinical Findings in Admitted Patients in Epilepsy Ward. Ashtari, Fereshteh; Zare, Mohammad; Akrami, Sedigheh // Journal of Isfahan Medical School;2/21/2011, Vol. 28 Issue 119, p1 

    Background: Many of the epileptic patients although are treated by multiple antiepileptic drugs but have recurrent multiple seizures. Surgery may be useful in these patients. Video-electroencephalic monitoring (VEM) is useful for finding epileptic focus or differentiating pseudoseizure from true...

  • Current Literature Changing Channels: Mechanisms and Responsiveness to Antiepileptic Drugs in Chronic Epilepsy. Sills, Graeme J. // Epilepsy Currents;May/Jun2004, Vol. 4 Issue 3, p98 

    Remy S, Urban BW, Elger CE, Beck H Eur J Neurosci 2003;171:2648–2658 Voltage-gated Na+ channels are a main target of many first-line anticonvulsant drugs, and their mechanism of action has been extensively investigated in cell lines and native neurons. Nevertheless, it is unknown whether...

  • A Markov model of treatment of newly diagnosed epilepsy in the UK: An initial assessment of cost-effectiveness of topiramate. Remék, E.; Hutton, J.; Price, M.; Peeters, K.; Adriaenssen, I. // European Journal of Health Economics;Dec2003, Vol. 4 Issue 4, p271 

    Long-term comparative trials among newer antiepileptic drugs are lacking; therefore decision models are needed to guide treatment decisions. The goal of this study was to develop an economic model of newly diagnosed epilepsy in the UK and to provide the first assessment of topiramate. A Markov...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics